Dow Jones

39,512.84

0.32%

Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.

Regístrate

RCUS

Arcus Biosciences (RCUS)

Arcus Biosciences Inc

Fecha:

Regulatory News

Text Search:

Ordernar por:

Non-Regulatory News

Showing the most relevant articles for your search:NYSE:RCUS

1 2 3 4 5 6 7 Próxima >

Fecha	Hora	Fuente	Título	Símbolo	Compañía
09/05/2024	15:35	Business Wire	Arcus Biosciences Announces New Employment Inducement Grants	NYSE:RCUS	Arcus Biosciences Inc
08/05/2024	15:08	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NYSE:RCUS	Arcus Biosciences Inc
08/05/2024	15:05	Edgar (US Regulatory)	Form 8-K - Current report	NYSE:RCUS	Arcus Biosciences Inc
08/05/2024	15:02	Business Wire	Arcus Biosciences Reports First-Quarter 2024 Financial Results and Provides a Pipeline Update	NYSE:RCUS	Arcus Biosciences Inc
02/05/2024	15:05	Business Wire	Arcus Biosciences to Participate in the Bank of America Healthcare Conference 2024	NYSE:RCUS	Arcus Biosciences Inc
24/04/2024	15:00	Business Wire	Arcus Biosciences to Present New Data from Phase 2 Studies of Novel Immuno-Oncology Combinations at the 2024 ASCO Annual Meeting	NYSE:RCUS	Arcus Biosciences Inc
23/04/2024	15:05	Business Wire	Arcus Biosciences to Host Conference Call to Discuss First-Quarter 2024 Financial Results and Pipeline Update	NYSE:RCUS	Arcus Biosciences Inc
28/02/2024	15:05	Business Wire	Arcus Biosciences to Participate in Two Upcoming Investor Conferences	NYSE:RCUS	Arcus Biosciences Inc
21/02/2024	15:53	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NYSE:RCUS	Arcus Biosciences Inc
21/02/2024	15:32	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NYSE:RCUS	Arcus Biosciences Inc
21/02/2024	15:05	Business Wire	Arcus Biosciences Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides a Pipeline Update	NYSE:RCUS	Arcus Biosciences Inc
07/02/2024	17:58	Edgar (US Regulatory)	Form 3 - Initial statement of beneficial ownership of securities	NYSE:RCUS	Arcus Biosciences Inc
07/02/2024	16:00	Business Wire	Arcus Biosciences to Host Conference Call to Discuss Fourth-Quarter and Full-Year 2023 Financial Results and Pipeline Updates	NYSE:RCUS	Arcus Biosciences Inc
30/01/2024	05:25	IH Market News	Arcus Biosciences Stock Jumps 20% on $320M Gilead Investment, Super Micro Surpasses Forecasts, and More News	NYSE:RCUS	Arcus Biosciences Inc
29/01/2024	16:00	Business Wire	Gilead and Arcus Announce Amended Collaboration and Equity Investment	NYSE:RCUS	Arcus Biosciences Inc
25/01/2024	18:39	Edgar (US Regulatory)	Form 4 - Statement of changes in beneficial ownership of securities	NYSE:RCUS	Arcus Biosciences Inc
16/01/2024	16:00	Business Wire	Data from a Phase 1b Study of Quemliclustat-Based Regimens Showed Promising Overall Survival in Treatment-Naïve Metastatic Pancreatic Cancer	NYSE:RCUS	Arcus Biosciences Inc
15/12/2023	15:22	Edgar (US Regulatory)	Form 144 - Report of proposed sale of securities	NYSE:RCUS	Arcus Biosciences Inc
04/12/2023	07:00	Business Wire	Exelixis and Arcus Biosciences Announce Clinical Trial Collaboration to Evaluate Zanzalintinib in Combination with AB521 in Patients with Advanced Renal Cell Carcinoma	NYSE:RCUS	Arcus Biosciences Inc
14/11/2023	15:00	Business Wire	Arcus Biosciences to Participate in the 6th Annual Evercore ISI HealthCONx Conference	NYSE:RCUS	Arcus Biosciences Inc
07/11/2023	15:01	Business Wire	Arcus Biosciences Reports Third Quarter 2023 Financial Results and Provides a Pipeline Update	NYSE:RCUS	Arcus Biosciences Inc
06/11/2023	16:00	Business Wire	Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-Line Treatment for Upper GI Cancers	NYSE:RCUS	Arcus Biosciences Inc
06/11/2023	16:00	Business Wire	Gilead and Arcus Announce New Data Showing Encouraging Clinical Activity of Anti-TIGIT Domvanalimab-Containing Regimen as First-line Treatment for Upper GI Cancers	NYSE:RCUS	Arcus Biosciences Inc
17/10/2023	15:00	Business Wire	Arcus Biosciences to Present Data from Ongoing EDGE-Gastric Study at ASCO Plenary and to Report Third-Quarter Financial Results on November 7	NYSE:RCUS	Arcus Biosciences Inc
23/08/2023	08:00	Business Wire	Arcus Biosciences to Participate in Multiple Upcoming Investor Conferences	NYSE:RCUS	Arcus Biosciences Inc
07/08/2023	07:00	Business Wire	Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update	NYSE:RCUS	Arcus Biosciences Inc
12/07/2023	06:41	IH Market News	Wednesday’s Wall Street Highlights: Nvidia, VMware, Alphabet, Coty, IBM, and more	NYSE:RCUS	Arcus Biosciences Inc
26/06/2023	15:37	Edgar (US Regulatory)	Statement of Changes in Beneficial Ownership (4)	NYSE:RCUS	Arcus Biosciences Inc
22/06/2023	15:08	Edgar (US Regulatory)	Report of Proposed Sale of Securities (144)	NYSE:RCUS	Arcus Biosciences Inc
16/06/2023	15:32	Edgar (US Regulatory)	Current Report Filing (8-k)	NYSE:RCUS	Arcus Biosciences Inc